MedPath

Colestipol

Generic Name
Colestipol
Brand Names
Colestid
Drug Type
Small Molecule
CAS Number
26658-42-4
Unique Ingredient Identifier
K50N755924

Overview

Bile acid sequestrants like colestipol have been in use since the 1970s. And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness. In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. Alternatively, colestipol predominantly elicits its activities within the gut environment because it undergoes little absorption and metabolism. The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

Background

Bile acid sequestrants like colestipol have been in use since the 1970s. And even though such an agent may very well be useful in reducing elevated cholesterol levels and decreasing the risk for atherosclerotic vascular disease due to hypercholesterolemia, colestipol is still generally only employed as an adjunct therapy and the relatively physical nature of its pharmacological activity sometimes limits its usefulness. In particular, as colestipol's general mechanism of action ultimately results in the decreased absorption and enhanced secretion of bile acids and lipids in the feces, patients who take complicated medication regimens, experience constipation or biliary obstruction, etc. may not be good candidates for using the agent owing to its physical effects on the gut. Alternatively, colestipol predominantly elicits its activities within the gut environment because it undergoes little absorption and metabolism. The resultant lack of systemic exposure consequently means the medication generally demonstrates very few adverse effects inside the body.

Indication

1.Ⅱa型高脂蛋白血症、冠心病危险性大而控制饮食治疗无效者。本品降低血浆总胆固醇和低密度脂蛋白胆固醇浓度,对血清甘油三酯浓度无影响或使之轻度升高,因此,对单纯甘油三酯升高者无效;2.胆管不完全阻塞所致的瘙痒。

Associated Conditions

  • Primary Hypercholesterolemia

FDA Approved Products

COLESTIPOL HYDROCHLORIDE
Manufacturer:Amneal Pharmaceuticals of New York LLC
Route:ORAL
Strength:1 g in 1 1
Approved: 2023/11/11
NDC:0115-2142
COLESTIPOL HYDROCHLORIDE
Manufacturer:Amneal Pharmaceuticals of New York LLC
Route:ORAL
Strength:5 g in 1 1
Approved: 2023/12/30
NDC:0115-5212
Colestid
Manufacturer:Pharmacia & Upjohn Company LLC
Route:ORAL
Strength:1 g in 1 1
Approved: 2022/11/16
NDC:0009-0450
Flavored Colestid
Manufacturer:Pharmacia & Upjohn Company LLC
Route:ORAL
Strength:5 g in 7.5 g
Approved: 2023/11/29
NDC:0009-0370
COLESTIPOL HYDROCHLORIDE
Manufacturer:Amneal Pharmaceuticals of New York LLC
Route:ORAL
Strength:5 g in 1 1
Approved: 2023/12/30
NDC:0115-5213

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath